• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

The ONTT: Intravenous steroids lead to faster visual recovery in optic neuritis [Classics Series]

byCarl ShenandAndrew Cheung, MD MBA
June 30, 2017
in Emergency Classics, General Medicine Classics, Surgery Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients with first presentation of optic neuritis, treatment with intravenous methylprednisolone followed by oral prednisone resulted in faster visual recovery when compared to placebo, though only a small benefit persisted by 6 months.

2. The use of oral prednisone alone demonstrated no benefit in terms of visual recovery and appeared to increase the risk of recurrent episodes of optic neuritis compared to placebo.

Original Date of Publication: February 1992

Study Rundown: Optic neuritis is an inflammatory condition affecting the optic nerve and is most commonly associated with multiple sclerosis (MS). Clinically, it can present with a wide range of impairment in visual acuity, color vision, contrast sensitivity, and/or visual fields. In the 1990s, both ophthalmologists and neurologists were commonly using oral steroids to treat optic neuritis, though oral and intravenous steroid regimens had not yet been evaluated in a randomized controlled trial.

The Optic Neuritis Treatment Trial (ONTT) compared the effectiveness and safety of different steroid regimens in treating optic neuritis. The study found that intravenous methylprednisolone followed by oral prednisone hastened the rate of visual recovery in optic neuritis compared to placebo, with some improvement in vision noted at 6 months after treatment. Use of oral prednisone alone was shown to have no benefit compared to placebo, though it did lead to significantly higher rates of recurrent optic neuritis. Since the publication of the ONTT, subsequent studies have found that intravenous steroids do accelerate visual recovery in optic neuritis, though there were no differences in long-term visual outcomes.

Click to read the study in NEJM

RELATED REPORTS

Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease

High-dose corticosteroids increase morbidity and mortality among hypoxic COVID-19 patients

Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis

In-Depth [randomized controlled trial]: This open-label, randomized trial recruited patients between 18-46 years of age with acute unilateral optic neuritis with visual symptoms lasting ≤8 days, a relative afferent pupillary defect (RAPD), and visual field defect in the affected eye. Exclusion criteria included previous optic neuritis in the same eye or evidence of a systemic disease, other than MS, that could cause optic neuritis. A total of 457 patients were randomized to either i) intravenous methylprednisolone 250 mg q6h for 3 days followed by oral prednisone 1 mg/kg for 11 days, ii) oral prednisone 1 mg/kg for 14 days, or 3) placebo. Steroid treatment was followed by a short oral taper. Patients were followed for 24 months. The primary outcomes were visual fields and contrast sensitivity measured at 6 months.

Patients treated with methylprednisolone had a higher rate of return to normal vision in visual fields (p = 0.0001) and contrast sensitivity (p = 0.02), with a trend towards improved visual acuity (p = 0.09) compared to placebo. At 6 months, patients in the methylprednisolone group experienced better contrast sensitivity (p = 0.026) and color vision (p = 0.033), with no differences noted in visual acuity (p = 0.664). There were no significant differences in the rates of recovery for oral prednisone patients compared to placebo in all measures of vision (p > 0.05). By 24 months, 20 (13%) patients in the methylprednisolone group, 42 (27%) patients in the oral prednisone group, and 24 (15%) patients in the placebo group had experienced ≥1 new episode of optic neuritis. The oral prednisone group had a higher rate of new episodes of optic neuritis compared with placebo (RR 1.79, 95%CI 1.08-2.95).

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: corticosteroidsonttoptic neuropathy
Previous Post

Benralizumab reduces oral steroid use in severe asthmatic patients

Next Post

Cardiovascular testing after emergency department presentation may not reduce risk of myocardial infarction

RelatedReports

2 Minute Medicine Rewind May 20, 2019
Pharma

Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease

January 20, 2025
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Infectious Disease

High-dose corticosteroids increase morbidity and mortality among hypoxic COVID-19 patients

May 17, 2023
Topical pimecrolimus use for atopic dermatitis not linked to malignancy
Chronic Disease

Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis

January 31, 2023
Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

January 19, 2023
Next Post
Variability in out-of-hospital pediatric cardiac arrest outcomes

Cardiovascular testing after emergency department presentation may not reduce risk of myocardial infarction

Smoking during pregnancy associated with aerobic fitness of children

E-cigarette use linked to increased risk of cigarette smoking in adolescents and young adults

Tonsillectomy may have short-term benefits in recurrent throat infection

Low risk allergy symptoms not linked to true penicillin allergy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.